BioEclipse Therapeutics was founded as ConcentRx Inc and was renamed in 2017, concomitant with launching our clinical strategy, with new funding and the build out of an experienced Executive Team and Independent Board of Directors. Our Board of Directors in now made up of life science company investors, and biopharmaceutical executives with product development and commercial expertise.
BioEclipse Therapeutics™ is preparing to enter open Phase I/IIa clinical trials with an intravenously delivered, targeted biotherapy against solid tumors. Our patented, first in class immunotherapy, CRX-100, delivers potentially curative treatments to patients over a broad range of tumor types. The first product from our platform, CRX-100, is made up of two components, both of which have been extensively tested in humans with an excellent safety profile.